Business Wire

Fishawack Acquires Creative Consultancy Blue Latitude Health

Jaa

The Fishawack Group of Companies, one of the world’s largest independent medical communications and medical marketing organizations, has acquired Blue Latitude Health, based in London, UK, and New York, USA. Blue Latitude Health is a creative consultancy combining the commercial focus of a consultancy with the creative vision of an agency.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181209005023/en/

Dominic Miller, Fred Bassett, Oliver Dennis (back row from left to right), Martin Brass, Gail Flockh ...

Dominic Miller, Fred Bassett, Oliver Dennis (back row from left to right), Martin Brass, Gail Flockhart (front row from left to right). (Photo: Business Wire)

“In 2016, we set out our vision to form a major new force in the global creative agency space that would make us as strong in the creative arena as we already are in medical communications,” explained Oliver Dennis , Chief Executive Officer of the Fishawack Group. “With three acquisitions in this space in the last 16 months, I think we’ve firmly announced our intention to achieve this goal. We were actively looking for a consultancy that could bring strategic and customer experience expertise to our portfolio and Blue Latitude Health fits perfectly.”

“To enable us to continue to grow and provide existing and future clients with a stronger offering, we needed to find a partner who both shared our values and matched our ambition,” stated Martin Brass , Managing Director of Blue Latitude Health. “We believe we have found this partner in Fishawack.”

Fred Bassett , Head of Strategy and Co-founder of Blue Latitude Health, added, “We are thrilled to join an organization with the global scale and extended services in medical and scientific communications that Fishawack offers.”

“Many of our clients are wanting a partner that has specialist global capabilities both commercially and medically, and can ensure alignment of communication objectives,” commented Gail Flockhart , Group Managing Director of Fishawack. “Blue Latitude Health has a deep strategic consulting capability and brings us a base in New York City, from which we can continue to expand our East Coast creative and medical communications teams.”

Fishawack received corporate finance and legal support from Rick Stark and Phil Hall of KPMG and George Danczak and James Finney of Addleshaw Goddard LLP (UK), respectively.

For more information about the Fishawack Group, please contact Gail Flockhart, Group Managing Director, at gail.flockhart@fishawack.com . For more information about Blue Latitude Health, please contact Martin Brass, Managing Director, at martin.brass@bluelatitude.com .

About the Fishawack Group

The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in the UK (Knutsford, Oxford, London, and Brighton), the USA (Philadelphia, PA, and San Diego, CA), Switzerland, and India (Hyderabad).

Fishawack comprises two international divisions, Fishawack Medical Communications, developing and delivering services in the fields of medical communications, scientific engagement, publications, market access, strategic consultancy, and thought leader consultancy, and Fishawack Creative, offering strategic planning, creative development, advertising and promotion, and tactical execution.

We have built our reputation on excellence, creativity, and transparency.

About Blue Latitude Health

Blue Latitude Health is a creative consultancy, made for modern healthcare. We combine the commercial focus of a consultancy with the creative vision of an agency, unlocking the potential in products and services that save and transform lives.

Focused on the commercialization of healthcare innovations, we operate globally and regionally at a brand, portfolio and organizational level. We have extensive end-to-end experience in launching breakthrough portfolios, services and brands, and helping our clients to map future customer and patient needs, as well as developing and executing winning commercial strategies.

Blue Latitude Health was founded in 2003 and has offices in London, UK, and New York, USA.

For more information, visit our website at www.bluelatitude.com

Fishawack Group of Companies

www.fishawack.com
LinkedIn: Fishawack Group of Companies
Twitter: @Fishawack

Headquarters:

No. 3 Booths Park, Chelford Road, Knutsford, WA16 8GS, UK
Tel: +44 1565 756600

Contact information

Fishawack Group
Gail Flockhart, Group Managing Director
gail.flockhart@fishawack.com

Blue Latitude Health
Martin Brass, Managing Director
martin.brass@bluelatitude.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Illumina and the Lundbeck Foundation GeoGenetics Centre Collaborate to Generate One of the Largest Ancient Genome Datasets to Decode the Genetic Origins and Evolution of Mental Health Issues26.3.2019 09:00:00 EETTiedote

Illumina (NASDAQ:ILMN) and the Lundbeck Foundation GeoGenetics Centre at the University of Copenhagen, Denmark partner to explore the relationship between the evolutionary history of select mental and neurological disorders and infectious pathogens. One of the first projects of its kind worldwide, the endeavor aims to acquire new knowledge in terms of the medical and biological understanding of special factors underlying the development of human neuropsychiatric diseases through the ages. Ultimately, the project may provide a new approach to the development of medicines and other therapeutic treatments for mental and neurological conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190325005867/en/ Where do brain disorders come from? In an effort to shed light on the role of microbes in the pathogenesis of neuropsychiatric illnesses, such as Alzheimer’s disease and schizophrenia, Professor Eske Willerslev and his team

Earth Networks Announces Completion of Severe Weather Early Warning System for PAGASA26.3.2019 02:00:00 EETTiedote

Earth Networks announced today the completion of the Philippines’ first nationwide severe weather monitoring and alerting network with associated software services for the Philippine Atmospheric, Geophysical, and Astronomical Services Administration (PAGASA), the National Meteorological and Hydrological Services (NMHS) agency of the Republic of the Philippines. The announcement was made at the 6th annual InterMET Asia conference in Singapore. Initiated in 2017, and formally commissioned this week, the technology partnership between PAGASA and Earth Networks is the first of its kind in the Philippines and surrounding regions, powered by a network of total lightning sensors and real-time automatic weather stations for mesoscale monitoring. Installed and operated together with Philippines partner West Point Engineering, the 10-year program includes: Real-time lightning detection powered by the Earth Networks Total Lightning Network On-the-ground weather monitoring via the Earth Networks W

Game of Thrones Winter is Coming™ Launches Worldwide26.3.2019 02:00:00 EETTiedote

Yoozoo Games, a leading game developer and publisher, today announced the global launch of Game of Thrones Winter is Coming™ , a real-time strategy PC browser game officially licensed by Warner Bros. Interactive Entertainment under license from HBO®. The game is now available in English, with additional languages to follow. HBO, Warner Bros. Interactive Entertainment and Yoozoo Games have collaborated to recreate Westeros on a massive scale, delivering an authentic and immersive multiplayer world laid out across the Seven Kingdoms – complete with major landmarks and castles from the epic TV series. The story begins immediately following the death of Eddard Stark, when the player emerges as a new Westeros lord or lady in his stead. Strategising starts in earnest in Game of Thrones Winter is Coming as players aim to build an impenetrable base, train a victorious army and recruit faithful followers from a pool of iconic characters. As players progress, they must continue to acquire the mi

bluebird bio Statement on European Regulatory Status of LentiGlobin™26.3.2019 01:40:00 EETTiedote

A third party press release was issued today stating that the EMA (European Medicines Agency) issued an approval for the conditional Marketing Authorization Application (MAA) for LentiGlobin™, bluebird bio’s investigational gene therapy for the treatment of transfusion dependent β-thalassemia (TDT). LentiGlobin for TDT is scheduled to be reviewed as part of the CHMP (Committee on Human Medicinal Products) meeting from March 25 – 28, however no opinion has been issued by the CHMP. If the CHMP’s opinion is issued it would then be reviewed by the European Commission (EC), which has the authority to grant approval for the use of LentiGlobin in the EU. About bluebird bio, Inc. bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., headquarters, we’re developing gene therapies for severe genetic diseases and cancer, with the goal that people facing potentially fatal conditions with limited treatment options can live their lives fully. Beyond our labs, we’re working

Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis25.3.2019 23:30:00 EETTiedote

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) for ozanimod for the treatment of adults with relapsing forms of multiple sclerosis (RMS). Ozanimod is an oral, sphingosine 1-phosphate (S1P) receptor modulator, which binds with high affinity selectively to S1P subtypes 1 (S1P1) and 5 (S1P5). The pivotal efficacy and safety data provided in the application result from the SUNBEAM™ and RADIANCE™ Part B phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled trials. “New oral treatment options with differentiated profiles like ozanimod are needed to help address an unmet need for people with relapsing forms of MS,” said Jay Backstrom, M.D., Chief Medical Officer for Celgene. “With concurrent applications in the U.S. and EU, we look forward to advancing this promising medicine through the regulatory review process to provide a new option for the treatment of RMS in

AVLT and UKTS Announce the European Medicines Agency’s Approval of the Conditional Marketing Authorization Application for Zynteglo™ (Previously Known as Lentiglobin™) Gene Therapy for the Treatment of Transfusion Dependent Beta Thalassaemia25.3.2019 22:50:00 EETTiedote

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) announced today that the European Medicines Agency (EMA) has approved bluebird bio’s application for Conditional Marketing Authorization (cMAA) of their product Zynteglo™, a gene therapy for the treatment of adolescents and adults with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype. As a result of this marketing authorisation, Zynteglo™ is now approved for use in all European countries covered by the European Medicines Agency. Zynteglo™ has been given ‘conditional authorisation’. This means that there is more evidence to be submitted, which the company is required to provide under specific obligations. Every year, the EMA will review any new information that becomes available. “People living with transfusion-dependent β-thalassaemia have a reduced life expectancy, requiring life-long frequent blood transfusions that are life-saving but may lead to complications, includin

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme